Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation
CA 2411192 A1 · Owner: Svartengren, Jan · Inventors: Svartengren, Jan; Nilsson, Bjorn M.; Sakariassen, Kjell S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method of preventing or treating a disease related to the 5-HT2C receptor and the 5-HT6 receptor comprising administering to a , human or animal subject in need thereof a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist in sufficient amounts to provide a therapeutic affect. The invention also relates to a pharmaceutical composition comprising an effective amount of a combination of a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist, and optionally a pharmaceutically acceptable carrier.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 19, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 19, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 19, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.